APP
PTHS

Avantax Planning Partners’s Pelthos Therapeutics PTHS Stock Holding History

Avantax Planning Partners’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,721
Closed -$33.5K – 456
2024
Q3 		$33.5K Buy
+4,721
New +$46K ﹤0.01% 436

Other funds holding PTHS

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Avantax Planning Partners's PTHS Position: Q4 2024 in Review

Avantax Planning Partners sold out of Pelthos Therapeutics (PTHS) in Q4 2024, closing a stake of 4,721 shares — an estimated $33.5K sold.

Avantax Planning Partners first reported a position in PTHS in Q3 2024 and held it in 1 quarter. The position peaked at $33.5K in Q3 2024. 4 funds tracked by Wall St. Rank hold PTHS as of Q4 2024.

  • Avantax Planning Partners reported no remaining Pelthos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Avantax Planning Partners sold 4,721 Pelthos Therapeutics shares in Q4 2024, an estimated $33.5K.
  • Avantax Planning Partners first reported a position in Pelthos Therapeutics in Q3 2024 and held it in 1 quarter.
  • Avantax Planning Partners's Pelthos Therapeutics position peaked at $33.5K in Q3 2024.
  • 4 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q4 2024.

Based on Avantax Planning Partners's 13F filing for Q4 2024, filed 7 Feb 2025.